文献速递消化系统肿瘤

抗表皮生长因子受体药物在70岁及以上RAS野生型转移性结直肠癌患者中的疗效

Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.
PubMed 文献 · Eur J Cancer · 2022-01-13

研究基于七个试验数据库,比较一线双药化疗联合或不联合抗EGFR药物治疗RAS野生型转移性结直肠癌老年(≥70岁)与年轻(<70岁)患者的疗效与安全性。老年患者联合抗EGFR治疗的无进展生存与年轻患者相似,但总生存较差;在年轻患者中联合抗EGFR改善生存,在老年患者中未达统计学显著;不同年龄组间毒性无显著差异。

要点

  • 老年(≥70岁)与年轻(<70岁)患者接受化疗联合抗EGFR治疗的无进展生存相似(8.7 vs 10.3个月,HR=1.20,P=0.107),但总生存较差(21.3 vs 26.3个月,HR=1.36,P=0.011)。
  • 年轻患者中联合抗EGFR较单纯化疗改善总生存(23.9 vs 20.3个月,HR=0.82,P=0.008)和无进展生存(11.2 vs 8.9个月,HR=0.70,P<0.001)。
  • 老年患者中联合抗EGFR较单纯化疗的总生存(24.7 vs 17.6个月,HR=0.77,P=0.092)和无进展生存(9.1 vs 8.7个月,HR=0.85,P=0.287)未达统计学显著。

核心结论

  • 老年与年轻RAS野生型转移性结直肠癌患者在接受化疗联合抗EGFR治疗时毒性相似,疗效具有可比性。

研究设计与样本

  • 基于Aide de Recherche en Cancerologie Digestive数据库七个试验,纳入一线双药化疗联合抗EGFR治疗(n=1191)或单纯双药化疗(n=729)的RAS野生型转移性结直肠癌患者。
  • 比较年龄≥70岁与<70岁患者的预后和预测效应,并在三个含单纯化疗组的试验中按年龄组比较联合与不联合抗EGFR的结局,随后对左半肿瘤进行相同分析。
  • 比较不同年龄组≥3级不良事件。

主要发现

  • 老年 vs 年轻患者接受化疗联合抗EGFR:无进展生存8.7 vs 10.3个月,HR=1.20(95%CI 0.96-1.49),P=0.107;总生存21.3 vs 26.3个月,HR=1.36(95%CI 1.08-1.72),P=0.011。
  • 年轻患者中联合抗EGFR vs 单纯化疗:总生存23.9 vs 20.3个月,HR=0.82(95%CI 0.70-0.95),P=0.008;无进展生存11.2 vs 8.9个月,HR=0.70(95%CI 0.60-0.82),P<0.001。
  • 老年患者中联合抗EGFR vs 单纯化疗:总生存24.7 vs 17.6个月,HR=0.77(95%CI 0.58-1.04),P=0.092;无进展生存9.1 vs 8.7个月,HR=0.85(95%CI 0.63-1.15),P=0.287。
  • 左半肿瘤中,老年 vs 年轻患者接受联合抗EGFR:无进展生存9 vs 11.2个月,HR=1.10(95%CI 0.83-1.46),P=0.52;总生存25.6 vs 30.3个月,HR=1.32(95%CI 0.97-1.79),P=0.086。
  • 左半肿瘤中,年轻患者联合抗EGFR vs 单纯化疗:无进展生存11.9 vs 9.2个月,HR=0.60(95%CI 0.47-0.78),P<0.001;总生存24.1 vs 23.3个月,HR=0.84(95%CI 0.67-1.04)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Colorectal cancer (CRC) affects many older adults. We investigated the efficacy and safety of adding anti-epidermal growth factor receptor (EGFR) agents to doublet chemotherapy (DC) in older patients. METHODS: Patients with RAS wild-type (WT) metastatic CRC (mCRC) receiving first-line DC + anti-EGFR (n = 1191) or DC alone (n = 729) from seven trials in the Aide de Recherche en Cancerologie Digestive database were included. The prognostic and predictive effects of age were investigated. Progression-free and overall survival (OS) were evaluated between age groups (≥70 vs <70) for DC + anti-EGFR. In addition, outcomes were compared between DC+/-anti-EGFR within age groups in three trials with a DC alone arm. Subsequently, the same analysis was conducted for left-sided tumours. Adverse events grade ≥3 (G3+) were compared between age groups. RESULTS: Older (vs younger) patients receiving DC + anti-EGFR had similar progression-free survival (PFS) (8.7 vs 10.3 months; hazard ratio (HR) = 1.20 [0.96-1.49];p = 0.107) but inferior OS (21.3 vs 26.3; HR = 1.36 [1.08-1.72];p = 0.011). DC + anti-EGFR (vs DC alone) improved OS (23.9 vs 20.3; HR = 0.82 [0.70-0.95];p = 0.008) and PFS (11.2 vs 8.9; HR = 0.70 [0.60-0.82];p < 0.001) in younger but not older patients: OS (24.7 vs 17.6; HR [95% confidence interval {CI}] = 0.77 [0.58-1.04];p = 0.092) and PFS (9.1 vs 8.7; HR [95% CI] = 0.85[0.63-1.15];p = 0.287). In left-sided 'only' tumours, the following outcomes for older (vs younger) patients were observed. For DC + anti-EGFR, PFS 9 versus 11.2 months; HR1.10 (95% CI 0.83-1.46); p = 0.52, OS 25.6 vs 30.3 HR 1.32 (95% CI 0.97-1.79), p = 0.086. For DC + anti-EGFR (vs DC alone), PFS and OS for younger patients were 11.9 vs 9.2 months HR 0.60 (95% CI 0.47-0.78) p < 0.001 and 24.1 versus 23.3 months HR 0.84 (95% CI 0.67-1.04), respectively. For older patients, PFS and OS were 13.1 versus 8.5 months, HR 0.51 (95% CI, 0.28-0.93), P = 0.027 and 26.3 versus 16.5 months HR 0.49 (95% CI, 0.28-0.85), respectively. There was no significant difference in toxicity among different age groups. CONCLUSIONS: Older (vs younger) patients with mCRC RAS WT patients had comparable toxicity and efficacy with the addition of anti-EGFR agents to chemotherapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Papamichael D, Lopes GS, Olswold CL, et al. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years. Eur J Cancer. 2022. PMID: 35033994. doi:10.1016/j.ejca.2021.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。